Novartis, Genentech object to NIH study confirming Avastin equal to Lucentis in AMD
This article was originally published in Scrip
Executive Summary
It's not often you hear a drug maker criticize its own product, but Genentech, now part of Roche, and its European partner on another drug, Novartis, raised concerns about the safety of Avastin (bevacizumab) when used to treat advanced age-related macular degeneration (AMD).